Zhu Xiaofeng is the deputy director of the Experimental Research Department and a professor in the State Key Laboratory of Oncology in South China. He is also the Director of the Committee of Cancer pharmacology in Guangdong Pharmacological Society, a Standing member of the Committee of Cancer pharmacology in Chinese Pharmacological Society, aStanding member of the Committee of anticancer drug in Chinese association for cancer research, Editorial board member for Chinese Journal of Cancer; Editorial board member for Frontier in Pharmacology and an Advisory board member for Advances in Therapy. His main research interest is Signal transduction in cancer and targeted anticancer drugs. He also is at the origin of 8 patents and products such as Shikonin derivatives and their antitumor effect or Houttuyninum compositions and methods for inhibiting the activity of erbB-2 based thereon and was awarded with numerous grants and honours, for example for Targeted therapy for cancer stem cells., 973 program, 4,500,000yuan RMB, from 2012 to 2016.